"By 2015, we will see the beginnings of a real transformation in the therapeutics of medicine, which by 2020, will have touched virtually every disorder … and the drugs that we give in 2020 will, for the most part, be those that were based on the understanding of the genome, and the things that we use today will be relegated to the dust bin." Francis Collins, Former NHGRI Director, 13th February (2005) Dr Collins's mid-decade vision was not un realistic at the time, given the exponential growth in genomic information that came in the 5 years after the draft of the human genome, which was published in 2000. However, our ability to apply knowledge of human genome variability to the discovery, development and clinical translation of personalized medicines is still rather elementary. At the beginning of the decade, pharmaco genomics (PGx) was generally perceived to be a rapidly evolving science with the potential to improve risk-benefit for given patients treated with already available drugs. In addition, a real promise of PGx was to bring innovation to the pharmaceutical and biotechnology drug-development process. There was significant concern regarding the growing costs, and increasing time lag, of developing a new molecular entity from the discovery stage to market approval. Innovation was deemed essential to reduce the attrition rate in late-phase clinical trials and to improve the overall productivity of the drug-development enterprise. Regulators at the US FDA recognized this potential too. However, FDA reviewers had relatively little experience with actually providing regulatory advice regarding PGx in investigational new drug applications, or assessing PGx data in new drug applications and biological licensing applications. Despite a lack of formal infrastructure for dealing with genetics and genomics in therapeutic marketing applications, the idea that certain subpopulations (defined genetically or otherwise) are more likely to respond to certain treatments was well appreciated in the agency. For example, the FDA approved the original application for trastuzumab (Herceptin ® ) in September 1998 with indications for singleagent use as second-or third-line therapy for metastatic breast cancer, and in combination with paclitaxel as first-line treatment. The label recommended that trastuzumab should only be used in patients whose tumors have HER2 protein overexpression (~25% of all breast cancers) because the beneficial treatment effects were largely limited to these patients. The Herceptin Over the past 10 years, the US FDA has become a strong pharmacogenomics advocate as part of its mission to both protect and advance public health by enabling innovations that make medicines safer to use and more effective. The agency has evolved its advocacy cautiously on a foundation of sciencebased information from novel programs, such as the Voluntary Genomics Data Submission initiative, and on careful regulatory assessment of the extraordinary advances in clinical pharmacogenomics that have supported the update of drug labels with genetic information. This commentary goes into detail on the evolution of these achievements. However, many challenges remain for pharmacogenomics, and they will continue to evolve, and all stakeholders must work together. As the decade draws to a close, we have presented four major areas that need to be addressed collectively to assure that pharmacogenomics continues to mature over the next 10 years into a science that is essential to the practice of medicine. 
Early FDA initiatives
In the early 2000s, it was clear to the FDA that the pharmaceutical and biotechnology industries had been conducting exploratory genomic investigations for over 10 years, but the industries were reluctant to share these data with the FDA. Their concerns were that reviewers would prematurely use exploratory data to make in appropriate regulatory decisions or request additional studies from the companies. To encourage the further integration of genomics in drug development, Lesko and Woodcock published two papers that provided a regulatory perspective on PGx, laid out the challenges ahead and highlighted recent FDA initiatives to advance PGx and promote its uptake into clinical practice [1, 2] . There was a major effort to foster the exchange of PGx information between the FDA and the industry, so a series of Drug Information Association (DIA) cosponsored workshops began in May 2002 with important goals, which was to identify barriers to PGx, and to gain public input on what is needed in terms of FDA Guidances for Industry [3] . A key achievement of the 2002 workshop was the introduction of a 'safe harbor' concept for submission of exploratory PGx data to the FDA. A draft of the guidelines on voluntary genomic data submissions (VGDS) were published by the FDA in November 2003; this proposed process was discussed extensively at the second DIA cosponsored workshop in November 2003 and the final guidelines were issued in March 2005 [101] .
By all indications, the industry reaction and the impact of the guidelines has been a reasonable success. As of December 2009, the FDA has received over 40 voluntary genomic data submissions. There has also been a dramatic increase in regular investigational new drug applications, new drug applications and biological licensing applications submissions that contain genomic information. Just between 2008 and 2009, there has been more than a 250% increase in review workload by the genomics group in the Office of Clinical Pharmacology at the FDA.
FDA update of labels
At the beginning of the decade, the FDA began looking for opportunities to improve the quality of therapeutics using already marketed drugs by updating the labels to include PGx information. 
Lessons learned
Industry sponsors have not fully embraced the VGDS concept as evidenced by the fact that numerous major pharmaceutical and biotechnology companies have never submitted a VGDS to the FDA. Their reasons are unclear, but may be owing to residual apprehension about the FDA review of voluntary genomic data, confusion over the requirements of a voluntary submission versus a required submission or the perception that it is not worth the time or effort to prepare and submit a VGDS. The potential for PGx in drug development envisioned 10 years ago has been mostly unfulfilled; this does not necessarily mean that the concept of 'personalized medicine' is invalid, but rather it reflects the overhyped view that PGx would transform drug development and therapeutics more rapidly. Given that it takes a company up to 8-12 years to complete the clinical development a molecule needs for regulatory future science group DNA, drugs & chariots: on a decade of pharmacogenomics at the US FDA Commentary approval, a decade of time is a relatively short timeframe. Nevertheless, while most of the progress in genomics during the past 10 years has been in the field of oncology (e.g., imatinib/C-KIT expression, erlotinib/EGF receptor [EGFR] expression and dasatinib/Ph+), there have been advances in the area of HIV and AIDS (e.g., maraviroc/CCR5 tropism), the use of PGx for guiding dosing (e.g., tetrabenazine/CYP2D6), and the use of PGx to differentiate a molecule from a competing molecule in the marketplace (e.g., prasugrel/CYP2C19).
Each label update has provided a unique opportunity to better understand the nuances of adding PGx to labels and the subsequent impact of label updates on adoption into clinical practice and diagnostic test reimbursement. The following represents some 'first in label updates' from the past 10 years along with some personal perspectives. n 6-MP/TPMT This was the first label to be updated in the last decade. There was a strong, mechanistically supported association between low TPMT enzyme activity (one in 300) and intermediate TPMT enzyme activity (11 in 100), increased concentrations of thioguanine derivatives at standard doses, and increased risk of myelo suppression. No specific doses of 6-MP were recommended in the label, although high-volume cancer centers (and later gastrointestinal practices) were developing dose-reduction schemas based on PGx and pharmacokinetic principles. TPMT testing does not obviate the need for monitoring complete blood count and platelet counts and looking for symptoms of myelosuppression. Clinical adoption of TPMT testing appears to be relatively low in cancer patients prescribed 6-MP (e.g., as compared with HER2 testing for trastuzumab) but there has been a more widespread uptake of TPMT testing in patients needing immuno suppressive therapy, including those receiving other thiopurines (e.g., azathioprine). n Irinotecan/UGT1A1*28 This was the first label update to recommend a specific dosing reduction based on PGx (at least one level dose reduction as defined in the package insert) in patients homozygous for UGT1A1*28 because of an increased risk of neutropenia. There is a fairly well-understood causal link between dose, exposure levels of irinotecan's active metabolite, and its association with risk of neutropenia. There were no specific recommendations for prescreening patients before receiving irinotecan and clinical adoption appears to be progressing slowly.
n Warfarin/CYP2C9-VKORC1 This was the first label update based on synthesis from multiple epidemiological data sources, including academic cohort studies and subgroup analyses of cohorts from prospective, randomized clinical studies. Pharmacogenetic associations were mechanistically supported and strengthened by observational drug-drug (CYP2C19) inter action studies. FDA regulatory scientists worked with clopidogrel's sponsor to generate specific data to answer outstanding questions regarding the pharmacogenetics of the active metabolite. In 2010, the label of clopidogrel was updated with a boxed warning to caution that poor metabolizers may not receive the full protection from heart attacks, stroke and cardiovascular death. From these examples that we have discussed it is clear that an update of a label with genetic information by the FDA does not guarantee the adoption of genetic testing into the practice of medicine. The latter is too complex to expect that it would be that easy. However, assessment of risk-benefit is, and will continue to be, a central issue for the FDA, and labels represent a necessary vehicle to provide medically appropriate information on PGx. Patients and their healthcare providers need to be able to make informed decisions on whether or not genetic information is useful in a given clinical context.
Future trajectory
A quadriga is a chariot drawn by four horses abreast and was used centuries ago in Greek and Roman chariot racing. Today, we see quadrigas as symbols of commitment to innovation, a pioneering spirit through scientific activities, progress and victory. A modern quadriga, with the charioteer representing patient advocates (clinicians, translational scientists and patients themselves) and the chariot representing PGx, cannot be triumphant without the four enabling 'horses' moving in the same direction in the next 10 years. These four key areas for advancing PGx are: commitment to improving efficacy and safety of medicines, demonstration of clinical utility and clinician education, clear regulatory guidance, and rewards and reimbursement. n Commitment to improving the efficacy & safety of medicines The pharmaceutical and biotechnology industries need to increase premarketing efforts to invest in targeted medicines for genetically or molecularly defined subsets of the disease population. Furthermore, as drug safety becomes a growing concern for regulatory agencies over the next decade, there will need to be a major effort to collect premarketing, postmarketing, DNA and safety phenotype data in order to develop associations and solutions. Sharing pre competitive and competitive safety data through consortia, such as the Serious Adverse Event Consortium [103] , will have a profound effect on progress towards managing the risks of drug therapy. In addition, academic researchers must begin to fill science gaps in a way that can be used by therapeutics and diagnostics developers and regulators to make meaningful risk-benefit assessments. This will require research to be conducted in a more rigorous way than it has been to date. Specifically, when conducting 'translational research' in clinical and academic settings, researchers should be aware of the high evidentiary burden required to trigger investment by drug and diagnostic companies in a PGx discovery, and to convince public health agencies of the need for a particular intervention (e.g., changing a drug label) based on a research finding. Issues around study methodology, data and statistical analyses, and potential clinical relevance of findings should be carefully considered prior to hypothesis testing. The majority of PGx studies to date have been exploratory, making definitive conclusions regarding the public health importance of PGx associations difficult. n Demonstration of clinical utility & clinician education The clinical utility of a genetic (i.e., diagnostic) test does not lie in the test itself but in the impact that the test result (i.e., information) has on a drug and/or dose selection decision, as future science group DNA, drugs & chariots: on a decade of pharmacogenomics at the US FDA Commentary measured by either a reduction in the mortality or morbidity of a disease, or on an improvement in the safety of a medicine. In the next 10 years, the scientific community needs to develop a consensus framework for generating evidence on the clinical utility (and cost-effectiveness) of genetic tests. Credible prospective and retrospective clinical studies, with prespecified statistical plans for the collection and ana lysis of genomic data, can provide a useful framework for accepting or rejecting the adoption of genetic tests. Many clinical utility studies of genetic tests are most likely to be conducted in naturalistic settings (e.g., Medco [NJ, USA]-Mayo clinic [MN, USA], Consumer Value Store [CVS; RI, USA]-Generation Health [NJ, USA]) after a medicine is marketed, since there is little incentive for a manufacturer to improve their benefit-risk profile following regulatory approval or after the drug loses patent protection. As we have previously articulated [4] , the demonstration of systems-wide clinical utility should not be a prerequisite for clinical adoption of PGx in individual practices because utility may only be demonstrable in a given clinical context (e.g., chronic vs acute care; rural vs urban settings). Also of note, it is important to recognize that clinical utility of medical interventions are often only revealed after a decades long lag time [5] . Therefore, it may be inappropriate -maybe even unethical -to not utilize PGx data in clinical settings as evidence of utility accumulates in increments.
Clinicians (e.g., physicians and pharmacists) are the gate-keepers of the demand for personalized medicine. Yet, most clinicians today, understandably, have limited experience of how to use genomics in clinical practice, so adoption of genetic tests has been minimal, except in the subspecialties (e.g., cancer and HIV and AIDS), and a major gap exists between the ideal situation and reality. Significantly more effort by clinicians in taking individual ownership of PGx is needed, as well as a greater commitment from medical and pharmacy school faculty and healthcare providers of continuing education to teach clinicians how to use genomic knowledge to make more informed decisions regarding therapeutics for their patients. n Clear regulatory guidance Regulatory models to deal with the personalized health space will continue to evolve incrementally. The FDA will make slow but steady progress in aligning regulatory guidance and policies with genomics and personalized medicines. In addition to continuing its VGDS program and updating labels with genomic information, the FDA expects to develop guidance for industry that will impact genomics in drug development over the next 5 years. These include: clinical pharmacogenomics guidance for early drug development, guidance related to premarket co-development of a drug and companion diagnostic, and guidance in dealing with enrichment strategies in clinical trials. The FDA also expects to clarify its regulatory authority in general, and those of its Center for Drug Evaluation and Research (MD, USA) and Center for Devices and Radiological Health (MD, USA), in the areas of laboratorydeveloped tests and multivariate gene assays in order to better enable informed investments in the development of diagnostic tests and personalized medicines. n Rewards & reimbursement It is critical that government agencies, insurance companies, and other payers provide sufficient rewards for pharmaceutical, diagnostic and biotechnology companies to build a climate of continued investment in developing innovative medicines and diagnostic tests, and to positively change attitudes and behaviors with respect to adoption of PGx. Reimbursement systems need to change from a technology-and process-based framework (e.g., Diagnosis Related Groups that reward quantity) to a value-based framework (i.e., that rewards quality) to catalyze the adoption of genomic medicine. Drug development and healthcare in general is expensive (e.g., it costs almost US$1 billion to bring a molecule from discovery to market). Studies have reported that most drugs, on average, have an effectiveness rate of 50% and adverse drug reactions continue to be the fifth leading cause of death in the USA. Since prescription drugs are a significant driver of medical cost inflation, a reward and reimbursement system that rewards higher efficacy rates or lower adverse event rates through genetic diagnostic tests seems like a reasonable solution that stakeholders can embrace. The business concept is one of 'value creation', but it assumes that the healthcare system (i.e., physicians, payers, patients and providers) can come to an agreement on what genetic information is of value in solving clinical problems.
The federal government and the FDA have a track record of incentivizing or rewarding investments in new and/or needed medicines, as evidenced by such milestones as the Orphan Drug Act to promote therapeutics for rare diseases or Act, 1992 ) and the critical path initiative (e.g., defining a biomarker qualification process). Many of these incentives can be invoked as catalysts for the development of targeted drugs and genetic diagnostic tests, and it is unclear whether further governmental or regulatory incentives are needed, or if the opportunities listed above are sufficient.
The field of PGx and personalized medicine has grown modestly over the past 10 years. Some have grown impatient or have given up on this science owing to the perceived slow pace of its progress. So, what will the next 10 years hold? To answer this question, one looks back over the past 10 years -it wasn't so long ago that we still used floppy discs, were conducting our first Google searches, and dropped our film off at a drug store to develop our pictures. In 2000, we would be years away from routinely 'downloading' all of our music, owning affordable high-definition televisions, and effortlessly navigating our cars to all points on the map using GPS technology. Genomic technologies have been equally substantial in our lives. One can obtain information on 1 million SNPs for comprehensive genetic predisposition testing for under US$500; the optimization of warfarin therapy is now possible through genetics for under US$250; tests are available for EGFR and KRAS mutations to guide cancer treatment; a gene-expression diagnostic test exists to look at a group of genes in a woman's breast cancer tumor and tells her, personally, what the likelihood is that she will have cancer return or whether or not she would benefit from adding chemotherapy to her hormonal treatment. This is what genomics can do: give patients and their doctors choices that they otherwise would never have had. In our future, the quadriga has a rearview mirror. However, it is safe to say 'don't look in the rearview mirror', except for a quick glance. We look ahead with optimism to the next 10 years, because the future will be an unrecognizable relative to the past in the field of genomics and personalized medicine.
